Inogen (INGN)
(Delayed Data from NSDQ)
$12.51 USD
+0.29 (2.37%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $12.49 -0.02 (-0.16%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.51 USD
+0.29 (2.37%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $12.49 -0.02 (-0.16%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth B Momentum A VGM
Zacks News
Inogen (INGN) Rises 127% Year to Date: What's Driving the Stock?
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for the Inogen (INGN) stock.
Inogen (INGN) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Inogen (INGN) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Inogen's (INGN) second-quarter 2024 results reflect significant improvement in the top and bottom lines, driven by strong international and domestic business-to-business sales.
Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 55.56% and 7.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) Soars 3.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
OrthoPediatrics (KIDS) Soars 7.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
OrthoPediatrics (KIDS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio Now
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.
Charles River (CRL) Advances in T-Cell Therapy With New Alliance
by Zacks Equity Research
Charles River (CRL) and Captain T Cell announced an agreement on plasmid DNA and retrovirus vector production program for the treatment of patients having solid tumor.
Asensus Surgical (ASXC) Inks a Merger Agreement With KARL STORZ
by Zacks Equity Research
KARL STORZ is set to acquire all of the outstanding shares of Asensus Surgical (ASXC) for $0.35 per share in cash, making Asensus a subsidiary of KARL STORZ.
Inogen (INGN) Down 0.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Buy Canopy Growth (CGC) Ahead of Q4 Earnings?
by Moumi Mondal
Canopy Growth's (CGC) rightsized cannabis-focused business is a major foundation for growth.
Inogen (INGN) Q1 Earnings Top Estimates, Revenues Up Y/Y
by Zacks Equity Research
Higher business-to-business sales aid Inogen's (INGN) overall first-quarter results.
Here's What Key Metrics Tell Us About Inogen (INGN) Q1 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Inogen (INGN) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Will These 5 Medical Device Stocks Beat This Earnings Season?
by Zacks Equity Research
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how INSP, MCK, FMS, NVRO and INGN are placed ahead of their earnings releases.
KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 50% and 9.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Up 26.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.
Inogen (INGN) Q4 Earnings Miss Estimates, Gross Margin Improves
by Zacks Equity Research
Inogen's (INGN) fourth-quarter earnings and revenues miss their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.
Inogen (INGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Inogen (INGN) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Inogen (INGN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of -75.38% and 2.81%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Gear Up for Inogen (INGN) Q4 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Inogen (INGN) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio for Now
by Zacks Equity Research
Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.
Inogen (INGN) Surges 12.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Inogen (INGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Inogen (INGN) Soars 15.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Inogen (INGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.